Report Highlights

Churg-Strauss Syndrome in the U.S.: Market Overview

The U.S. Churg-Strauss syndrome market, now clinically termed eosinophilic granulomatosis with polyangiitis (EGPA), is a small, specialist-driven segment of the broader vasculitis market. Analyst estimates place U.S. spending at roughly USD 0.42 billion in 2024, driven almost entirely by branded biologics rather than generic immunosuppressants. Unlike global norms, where corticosteroids and cyclophosphamide still dominate, the American market is defined by high-cost IL-5 pathway therapies priced per annual course with specialty pharmacy dispensing.

Prevalence in the U.S. is estimated at roughly 40 to 50 cases per million adults, concentrated among patients aged 40 to 65 with asthma and eosinophilia. Diagnosis spans multiple specialties, with rheumatologists, pulmonologists, and nephrologists often sharing care, which fragments prescribing authority. Patients commonly present with asthma progressing to neuropathy and cardiac involvement, so earlier recognition drives referral volume. This fragmentation makes the market structurally different from high-volume chronic indications and rewards companies that build multispecialty medical education.

Growth Drivers in U.S. Churg-Strauss Syndrome Care

The first driver is the FDA's 2024 approval of Fasenra for EGPA, which added a second biologic option beyond Nucala's 2017 label. The second is the expansion of biologic coverage under Medicare Part D and commercial plans, where payers increasingly accept eosinophil-count criteria as step-therapy triggers. The third is the growth of U.S. vasculitis centers, including the Mayo Clinic and Johns Hopkins rheumatology programs, which accelerate referral and diagnosis.

Demographic and clinical trends reinforce demand. The U.S. population aged 65 and over is growing, and EGPA onset in middle age combined with rising adult-onset asthma prevalence expands the pool of patients with eosinophilic phenotypes. Additionally, the NIH-funded Vasculitis Clinical Research Consortium has improved biomarker-based classification, allowing clinicians to separate EGPA from other ANCA-associated vasculitides earlier. Those diagnostic gains translate directly into earlier biologic initiation and higher treated-patient counts.

Market Restraints and Entry Barriers

Biologic pricing is the central barrier. Nucala and Fasenra carry annual list prices exceeding USD 50,000 per patient, and payers apply prior authorization requirements requiring documented asthma history, blood eosinophil counts, and corticosteroid dependence. Under the Inflation Reduction Act's Part D redesign, manufacturers fund a 10 percent discount in the initial coverage phase, reshaping net pricing. Specialty pharmacy networks, controlled by CVS Specialty and Optum Specialty, hold dispensing rights, so new entrants must negotiate access rather than rely on retail distribution.

Incumbent advantage in corticosteroid-sparing therapy is substantial. Generic prednisone and cyclophosphamide, supplied by manufacturers such as Teva and Baxter, remain first-line in many treatment algorithms, and clinicians resist switching without outcome data. Mepolizumab's pediatric and adult data packages have set a high evidence bar for any follow-on biologic seeking formulary parity. Entrants also face the Orphan Drug Act's seven-year exclusivity, which blocks competitors in the same indication and extends the incumbents' protection window.

Market Opportunities in the U.S.

The most actionable near-term opportunity lies in next-generation anti-IL-5 and anti-IL-4/IL-13 agents targeting patients who fail mepolizumab. Analyst models suggest roughly 15 to 20 percent of diagnosed U.S. EGPA patients show inadequate response to first-line biologics, creating an addressable pool of several thousand patients. Companies with oral or lower-frequency dosing will capture disproportionate share of that switching demand. Dupixent's approval in other eosinophilic diseases signals that IL-4/IL-13 blockade is commercially viable in this patient profile.

A second opportunity is the hospital-based and academic referral network. Vasculitis centers at Mayo Clinic, Cleveland Clinic, and the University of Pennsylvania can serve as reference sites for real-world evidence studies, and the addressable pool of diagnosed patients under specialist care is estimated at 3,000 to 4,000 annually. Those patients generate the highest prescribing volume. Digital diagnostic tools that flag eosinophilia in asthma clinics offer a third channel to reach patients earlier.

Market at a Glance

Leading Market Participants

• GSK
• AstraZeneca
• Genentech
• Amgen
• Sanofi
• Regeneron Pharmaceuticals
• Teva Pharmaceuticals
• Baxter International
• Viatris
• Sun Pharmaceutical

Regulatory and Policy Environment

Biologics for EGPA are regulated by the FDA's Center for Drug Evaluation and Research under the Federal Food, Drug, and Cosmetic Act, with Nucala approved in June 2017 and Fasenra's EGPA indication granted in September 2024. Orphan designation under the Orphan Drug Act provides seven years of market exclusivity and tax credits for clinical trials. Pricing and reimbursement are overseen by the Centers for Medicare and Medicaid Services, with the Inflation Reduction Act introducing Part D manufacturer discount programs and Medicare drug price negotiation for selected drugs.

Compliance timelines matter for launch planning. Biologic sponsors must file Biologics License Applications with the FDA and secure Medicare coverage determinations, while state pharmacy boards and the Drug Supply Chain Security Act impose serialization and traceability requirements from November 2024 onward. Ongoing pharmacovigilance reports go to the FDA's MedWatch system. Medicare Part D formulary submissions typically precede launch by six to nine months, and prior-authorization criteria are negotiated with PBMs under plan-level Part D formulary rules.

Long-Term Outlook for U.S. Churg-Strauss Syndrome Care

By 2032 the U.S. market is projected to reach roughly USD 0.69 billion, growing at a single-digit pace as patient identification improves and biologic penetration rises from current levels. Growth will be steady rather than explosive, because the eligible patient pool is small and price concessions will offset volume gains. Competitive IL-5 pathway pricing and the entry of additional biologic agents will shift value toward payers and specialty distributors.

Long-term winners will combine evidence generation with access strategy. Companies that secure real-world data from U.S. vasculitis registries and build partnerships with Optum Specialty and CVS Specialty will hold leverage by the early 2030s. Investors should expect the American market to remain concentrated, with two or three branded biologics controlling most spending through 2032. Adjacent label expansions in severe asthma and hypereosinophilic syndrome could extend indication breadth and support premium pricing beyond the EGPA core population.